Last reviewed · How we verify

Exparel with Bubivacaine

Maimonides Medical Center · FDA-approved active Small molecule

Exparel is a liposomal formulation of bupivacaine that provides prolonged local anesthetic effect by slowly releasing bupivacaine from lipid vesicles at the injection site.

Exparel is a liposomal formulation of bupivacaine that provides prolonged local anesthetic effect by slowly releasing bupivacaine from lipid vesicles at the injection site. Used for Infiltration anesthesia and nerve block in adults for surgical anesthesia and postoperative analgesia.

At a glance

Generic nameExparel with Bubivacaine
SponsorMaimonides Medical Center
Drug classLocal anesthetic (liposomal formulation)
TargetVoltage-gated sodium channels
ModalitySmall molecule
Therapeutic areaPain Management / Anesthesia
PhaseFDA-approved

Mechanism of action

Bupivacaine is a long-acting local anesthetic that blocks sodium channels in nerve cell membranes, preventing depolarization and transmission of nerve impulses. The liposomal encapsulation (DepoFoam technology) allows sustained release of the drug over an extended period, providing analgesia for up to 72 hours after a single infiltration, compared to 4-8 hours with standard bupivacaine.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: